prod:prod_dcx-login
Xpert® GBS LB XC
Detection of Group B Streptococcus with dual target with results within one hour
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
10 Tests
GXGBSLBXC-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
Collection Device (Pack of 50)
900-0370
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Single Use Disposable Swab (Pack of 120)
SDPS-120
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
In the U.S., Group B Streptococcus (GBS) remains a leading cause of early onset neonatal sepsis. Rates of maternal colonization have not changed, but universal antenatal screening at 35–37 weeks along with the use of intrapartum antibiotic prophylaxis (IAP) has resulted in a decrease of early onset disease.1,2
- Centers for Disease Control and American College of Obstetricians and Gynecologists practice guidelines recommend universal antepartum screening along with intrapartum where indicated based on risk
- Risk based IAP exposes 65–85% of GBS-negative women with risk factors to antibiotics. This has been linked to emergence of resistant strains3
- Up to 50% false negatives when testing with agar alone4
1 CDC. Prevention of Perinatal Group B Streptococcal Disease: Revised Guidelines from CDC, 2010. Nov 19, 2010 / 59(RR10);1-32.
2 ACOG Committee Opinion No. 485: Prevention of early-onset group B streptococcal disease in newborns. Obstet Gynecol. 2011 Apr;117(4):1019-27.
3 Alfa MJ, et al. Real-time PCR assay provides reliable assessment of intrapartum carriage of group B Streptococcus. J Clin Microbiol. 2010 Sep;48(9):3095-9.
4 Paolucci M, et al. How can the microbiologist help in diagnosing neonatal sepsis? Int J Pediatr. 2012;2012:120139
US-IVD. For In Vitro Diagnostic Use.
2 ACOG Committee Opinion No. 485: Prevention of early-onset group B streptococcal disease in newborns. Obstet Gynecol. 2011 Apr;117(4):1019-27.
3 Alfa MJ, et al. Real-time PCR assay provides reliable assessment of intrapartum carriage of group B Streptococcus. J Clin Microbiol. 2010 Sep;48(9):3095-9.
4 Paolucci M, et al. How can the microbiologist help in diagnosing neonatal sepsis? Int J Pediatr. 2012;2012:120139
US-IVD. For In Vitro Diagnostic Use.
The Solution
Cepheid's GeneXpert® system, with both Xpert® GBS LB XC and Xpert GBS is the only solution able to fully meet CDC criteria for both antenatal and intrapartum testing, with positive results in approximately 40 minutes.
On-demand molecular testing — an ideal solution:
- Reduces lab's work for antenatal screening
- Random access ensures any test on the menu can be run anytime, without the need to batch run
On-demand molecular testing — an ideal solution:
- System designed with Early Assay Termination (EAT) with positive samples reported STAT
- Moderately complex testing with minimal hands-on time
- Reduces lab's work for antenatal screening
- Random access ensures any test on the menu can be run anytime, without the need to batch run
The Impact
The Xpert GBS LB XC test, performed on Cepheid's GeneXpert systems, delivers an elegant, simple and streamlined solution.
A molecular in vitro diagnostic, Xpert GBS LB XC is designed for use in the clinical lab. It allows users to perform three simple steps and the GeneXpert does the rest.
Impact on Patient Pathway
![]()
A molecular in vitro diagnostic, Xpert GBS LB XC is designed for use in the clinical lab. It allows users to perform three simple steps and the GeneXpert does the rest.
- Easy to use screening test
- Delivers results on positive LIM broth samples in 27* minutes
- Fast accurate NAAT results
- Moderate complexity
Impact on Patient Pathway
Related Products
Xpert CT/NG
90-minute detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG)